Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma

Open access
Vinod, Natasha, Hwang, Duhyeong, Azam, Salma H., Van Swearingen, Amanda E. D., Wayne, Elizabeth, Fussell, Sloane Christian, Sokolsky-Papkov, Marina, Pecot, Chad V., Kabanov, Alexander V. · 2020 · Science Advances

Published version of a preprint

Abstract

Polymeric micelle formulation of an immune modulator improves survival in a highly aggressive model of non–small cell lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aba5542

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Physical characterization of Resiquimod PM. (A) Particle size distribution of Resiquimod PM at different feeding ratios as a function of intensity (percentage), measured by DLS. (B and C) Transmission electron micrographs at different magnifications show the spherical morphology of Resiquimod PM particles (4/10 g/liter) and illustrate the uniformity of particle shape and size. (D) Characterization of POx micelles loaded with TLR 7/8 agonist (Resiquimod).
Fig. 1 Physical characterization of Resiquimod PM. (A) Particle size distribution of Resiquimod PM at different feeding ratios as a function of intensity (percentage), measured by DLS. (B and C) Transmission electron micrographs at different magnifications show the spherical morphology of Resiquimod PM particles (4/10 g/liter) and illustrate the uniformity of particle shape and size. (D) Characterization of POx micelles loaded with TLR 7/8 agonist (Resiquimod).CC BY-NC · PubMed Central
Fig. 2 Cytotoxicity assay of POx formulations. In vitro cytotoxicity of anticancer agent and chemosensitizers in the 344SQ LUAD cell line (A, B, D, and E). Dose-response curves of free and micelle incorporated drugs and drug combinations in the 344SQ cell line after 72 hours of treatment. Cell viability as a function of individual drug concentrations after treatment with a combination of the drugs AZD8055 and C6CP (A and B) and VE-822 and PTX (D and E). The data were fit into sigmoidal curve using nonlinear regression. Data represent mean ± CV. n = 6. (C and F) Fa-CI plots of the C6CP/AZD7762 and C6CP/VE-822 combinations. Data represent means. n = 6. (G) Comparison of the IC50 values of POx formulations and free drugs in the 344SQ cell line.
Fig. 2 Cytotoxicity assay of POx formulations. In vitro cytotoxicity of anticancer agent and chemosensitizers in the 344SQ LUAD cell line (A, B, D, and E). Dose-response curves of free and micelle incorporated drugs and drug combinations in the 344SQ cell line after 72 hours of treatment. Cell viability as a function of individual drug concentrations after treatment with a combination of the drugs AZD8055 and C6CP (A and B) and VE-822 and PTX (D and E). The data were fit into sigmoidal curve using nonlinear regression. Data represent mean ± CV. n = 6. (C and F) Fa-CI plots of the C6CP/AZD7762 and C6CP/VE-822 combinations. Data represent means. n = 6. (G) Comparison of the IC50 values of POx formulations and free drugs in the 344SQ cell line.CC BY-NC · PubMed Central
Fig. 3 In vitro activation of BMDM. (A) Relative mRNA expression of classically activated (M1-like) macrophage markers (TNFα, IL-1β, IL-6, and NOS2) normalized to 18S. (B) Relative mRNA expression of M2-like macrophage markers (c-myc and IL-10) normalized to 18S. Data represent means ± SEM. n = 3. **P < 0.01 and ***P < 0.001 computed by unpaired Student’s t test with Welch’s correction. Significance level (α) was set at 0.05. (C) Cell morphology of resting macrophages and M1-polarized macrophages following Resiquimod and Resiquimod PM (2/10 g/liter) treatments (bottom). Scale bars: 50 μm.
Fig. 3 In vitro activation of BMDM. (A) Relative mRNA expression of classically activated (M1-like) macrophage markers (TNFα, IL-1β, IL-6, and NOS2) normalized to 18S. (B) Relative mRNA expression of M2-like macrophage markers (c-myc and IL-10) normalized to 18S. Data represent means ± SEM. n = 3. **P < 0.01 and ***P < 0.001 computed by unpaired Student’s t test with Welch’s correction. Significance level (α) was set at 0.05. (C) Cell morphology of resting macrophages and M1-polarized macrophages following Resiquimod and Resiquimod PM (2/10 g/liter) treatments (bottom). Scale bars: 50 μm.CC BY-NC · PubMed Central
Fig. 4 Tumor inhibition in 344SQ lung adenocarcinoma–bearing mice. Kaplan-Meier survival plots of (A) tumor-bearing mice treated with four intravenous injections of saline, C6CP/AZD7762 PM, and C6CP/VE-822 PM. (B) Tumor-bearing mice treated with four intravenous injections of saline, Resiquimod PM, eight intraperitoneal injections of anti–PD-1 antibody, and a combination of Resiquimod PM (four intravenous injections) anti–PD-1 antibody (eight intraperitoneal injections). P values were computed by log-rank (Mantel-Cox) test. Significance level (α) was set at 0.05. (C) Quantification of BLI signal; data represent means ± SEM. n = 13. (D) Representative IVIS images of mice from each treatment group on the days of the treatment.
Fig. 4 Tumor inhibition in 344SQ lung adenocarcinoma–bearing mice. Kaplan-Meier survival plots of (A) tumor-bearing mice treated with four intravenous injections of saline, C6CP/AZD7762 PM, and C6CP/VE-822 PM. (B) Tumor-bearing mice treated with four intravenous injections of saline, Resiquimod PM, eight intraperitoneal injections of anti–PD-1 antibody, and a combination of Resiquimod PM (four intravenous injections) anti–PD-1 antibody (eight intraperitoneal injections). P values were computed by log-rank (Mantel-Cox) test. Significance level (α) was set at 0.05. (C) Quantification of BLI signal; data represent means ± SEM. n = 13. (D) Representative IVIS images of mice from each treatment group on the days of the treatment.CC BY-NC · PubMed Central
Fig. 5 Resiquimod PM induces TH1 polarization of immune cells in the TME. (A) Representative fluorescence-activated cell sorting (FACS) plots of CD11b+/CD11c−/Ly6C+, CD45+/CD3+/CD4+, and CD45+/CD3+/CD8+ cell populations from the tumors of mice treated with saline and Resiquimod PM. FSC-A: forward scatter area. (B to E) Quantification of the indicated population of cells. Data represent means ± SEM. n = 4. *P < 0.05 computed by unpaired Student’s t test with Welch’s correction. Significance level (α) was set at 0.05. ns, not significant.
Fig. 5 Resiquimod PM induces TH1 polarization of immune cells in the TME. (A) Representative fluorescence-activated cell sorting (FACS) plots of CD11b+/CD11c−/Ly6C+, CD45+/CD3+/CD4+, and CD45+/CD3+/CD8+ cell populations from the tumors of mice treated with saline and Resiquimod PM. FSC-A: forward scatter area. (B to E) Quantification of the indicated population of cells. Data represent means ± SEM. n = 4. *P < 0.05 computed by unpaired Student’s t test with Welch’s correction. Significance level (α) was set at 0.05. ns, not significant.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 63

Metadata

Authors
Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.
Corresponding author
  • Pecot, Chad V.
  • Kabanov, Alexander V.
Venue
Science Advances
Published
2020-06-17
Volume
6
Issue
25
Pages
eaba5542-eaba5542
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3036026766
Cited by
63
References
64
Citations by year
2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 20 · 2021: 18 · 2020: 2
FWCI
4.20
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by-nc)
  • UNC Libraries
Funders
National Institutes of Health (5U54CA198999-05)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
poly(2-oxazoline), resiquimod, TLR7/8 agonist, lung adenocarcinoma, metastatic non-small cell lung cancer, drug formulation, survival, cancer immunotherapy
MeSH terms
Adenocarcinoma of Lung, Adjuvants, Immunologic, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Oxazoles, Toll-Like Receptor 7, Toll-Like Receptor 8, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. https://app.cochat.ai/papers/10.1126/sciadv.aba5542
The paper
Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020). High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Science Advances. https://doi.org/10.1126/sciadv.aba5542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.